ClinConnect ClinConnect Logo
Search / Trial NCT06252285

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Launched by SANOFI PASTEUR, A SANOFI COMPANY · Feb 7, 2024

Trial Information

Current as of June 19, 2025

Active, not recruiting

Keywords

ClinConnect Summary

This clinical trial is testing a new vaccine for Respiratory Syncytial Virus (RSV) in infants and toddlers aged 6 months to less than 22 months. RSV is a common virus that can cause serious respiratory infections in young children. The study will compare the new RSV vaccine, given as a nasal spray, to a placebo (a substance with no active ingredients) to see how well it works and how safe it is. About 6,300 children will take part in this study, which will last for 24 months for each participant.

To be eligible for the study, children must be healthy and born at full term. However, some children may not be able to join the study if they have certain health conditions, such as a weakened immune system or a recent serious illness. Participants will receive two doses of either the vaccine or the placebo, and researchers will closely monitor their health throughout the study to ensure safety. If you have a child who meets these criteria and you’re interested in learning more, this study could help advance RSV prevention in young children.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria: -Aged 6 months to \< 22 months on the day of inclusion (means the day of the 6-month birthday to the day before the 22-month birthday)
  • Participants who are healthy as determined by medical evaluation including medical history
  • Born at full term of pregnancy (≥ 37 weeks)
  • Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • History of medically diagnosed wheezing
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of viral respiratory infection (including COVID-19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
  • * Member of a household that contains an immunocompromised individual, including, but not limited to:
  • a person who is HIV infected
  • a person who has received chemotherapy within the 12 months prior to study enrollment
  • a person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
  • a person living with a solid organ or bone marrow transplant
  • Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
  • Participant's biological mother's previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding.
  • * Receipt or planned receipt of any of the following vaccines prior to enrollment or after the first study intervention administration:
  • Any other intranasal live attenuated vaccine within the 28 days prior to and after Dose 1 study administration
  • Unless given on the day of Dose 1 study administration, any other injectable live attenuated vaccines within the 28 days prior to and after. Concomitant receipt on the day of Dose 1 study administration is allowed.
  • Previous receipt of an investigational RSV vaccine or receiving any anti-RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment. Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

About Sanofi Pasteur, A Sanofi Company

Sanofi Pasteur, a subsidiary of Sanofi, is a global leader in the development and production of vaccines. With a rich heritage in vaccine innovation, the company is dedicated to advancing public health by providing safe, effective, and accessible immunizations for a wide range of infectious diseases. Sanofi Pasteur invests significantly in research and development to address evolving health challenges and to enhance vaccine coverage worldwide. Committed to collaboration with health organizations and communities, the company strives to protect individuals and populations through its comprehensive portfolio of vaccines, contributing to the prevention of diseases and the promotion of healthier lives globally.

Locations

Idaho Falls, Idaho, United States

Veracruz, , Mexico

Pamplona, Navarra, Spain

San Pedro Sula, , Honduras

Kokkola, , Finland

League City, Texas, United States

Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina

Rosario, Santa Fe, Argentina

San Miguel De Tucumán, Tucumán, Argentina

San Miguel De Tucumán, Tucumán, Argentina

San Pedro Sula, , Honduras

Tegucugalpa, , Honduras

Cali, , Colombia

Birmingham, Alabama, United States

Guntersville, Alabama, United States

Tucson, Arizona, United States

Madera, California, United States

San Diego, California, United States

Tarzana, California, United States

Victorville, California, United States

Coconut Creek, Florida, United States

Orlando, Florida, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Atlanta, Georgia, United States

Chamblee, Georgia, United States

Macon, Georgia, United States

Savannah, Georgia, United States

Stockbridge, Georgia, United States

Ammon, Idaho, United States

Idaho Falls, Idaho, United States

Idaho Falls, Idaho, United States

Idaho Falls, Idaho, United States

Allen Park, Michigan, United States

Dearborn Heights, Michigan, United States

Southfield, Michigan, United States

Minneapolis, Minnesota, United States

Great Falls, Montana, United States

Kalispell, Montana, United States

Missoula, Montana, United States

Hastings, Nebraska, United States

Lincoln, Nebraska, United States

Norfolk, Nebraska, United States

Omaha, Nebraska, United States

Omaha, Nebraska, United States

Bronx, New York, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

Gresham, Oregon, United States

Charleston, South Carolina, United States

North Charleston, South Carolina, United States

Simpsonville, South Carolina, United States

Nashville, Tennessee, United States

Beaumont, Texas, United States

Dallas, Texas, United States

Del Rio, Texas, United States

Fort Worth, Texas, United States

Houston, Texas, United States

League City, Texas, United States

Richmond, Texas, United States

San Antonio, Texas, United States

Layton, Utah, United States

Roy, Utah, United States

Syracuse, Utah, United States

Charlottesville, Virginia, United States

Ciudad Autónoma De Buenos Aires, Ciudad De Buenos Aires, Argentina

Ciudad Autónoma De Buenos Aires, Ciudad De Buenos Aires, Argentina

Río Cuarto, Córdoba, Argentina

Santiago, Reg Metropolitana De Santiago, Chile

Santiago, Reg Metropolitana De Santiago, Chile

Acacías, , Colombia

Aguazul, , Colombia

Armenia, , Colombia

Barranquilla, , Colombia

Bogotá, , Colombia

Chía, , Colombia

Girardot, , Colombia

Helsinki, , Finland

Seinäjoki, , Finland

Tampere, , Finland

Sapporo Shi Nishi Ku, Hokkaido, Japan

Shizuoka Shi Aoi Ku, Shizuoka, Japan

Iizuka Shi, , Japan

Osaka Shi, , Japan

La Joya, , Mexico

Monterrey, , Mexico

Bayamon, , Puerto Rico

Guayama, , Puerto Rico

San Juan, , Puerto Rico

San Juan, , Puerto Rico

Barcelona, Barcelona [Barcelona], Spain

Mostoles, Madrid, Spain

Santiago De Compostela, , Spain

Sevilla, , Spain

Bangkok Noi, , Thailand

Mueang Chiang Mai, , Thailand

Mueang Khon Kaen, , Thailand

Ratchathewi, , Thailand

Ratchathewi, , Thailand

Songkla, , Thailand

Hayle, Cornwall, United Kingdom

Exeter, Devon, United Kingdom

Runcorn, Halton, United Kingdom

Santiago, Reg Metropolitana De Santiago, Chile

Santiago, Reg Metropolitana De Santiago, Chile

Tarzana, California, United States

Doral, Florida, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Idaho Falls, Idaho, United States

Houston, Texas, United States

Salvador, Bahia, Brazil

Ribeirão Preto, São Paulo, Brazil

São Paulo, , Brazil

São Paulo, , Brazil

Independencia, Reg Metropolitana De Santiago, Chile

Bogota, , Colombia

Medellin, , Colombia

Espoo, , Finland

Järvenpää, , Finland

Oulu, , Finland

Turku, , Finland

Dhulikhel N.P, Bagmati, Nepal

Kathmandu, Bagmati, Nepal

Nepalgunj, Bheri, Nepal

Bristol, , United Kingdom

Victorville, California, United States

Aurora, Colorado, United States

Coconut Creek, Florida, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Macon, Georgia, United States

Rexburg, Idaho, United States

Moline, Illinois, United States

Baltimore, Maryland, United States

Minneapolis, Minnesota, United States

Norfolk, Nebraska, United States

Reno, Nevada, United States

Bronx, New York, United States

Gresham, Oregon, United States

Houston, Texas, United States

Roy, Utah, United States

Fukui Shi, , Japan

Kisumu, , Kenya

Kisumu, , Kenya

Belo Horizonte, Minas Gerais, Brazil

São José Do Rio Preto, São Paulo, Brazil

Jiangsu, , China

Kawagoe Shi, Saitama, Japan

Fukuoka Shi Higashi Ku, , Japan

Kasuga Shi, , Japan

Buffalo City, , South Africa

City Of Cape Town, , South Africa

City Of Johannesburg, , South Africa

City Of Tshwane, , South Africa

Johannesburg, , South Africa

Madibeng, , South Africa

Paarl, , South Africa

Soshanguve, , South Africa

Seville, Sevilla, Spain

São José Do Rio Preto, São Paulo, Brazil

São Paulo, , Brazil

Birmingham, Alabama, United States

Guntersville, Alabama, United States

Tucson, Arizona, United States

Madera, California, United States

Tarzana, California, United States

Victorville, California, United States

Coconut Creek, Florida, United States

Orlando, Florida, United States

Tampa, Florida, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Atlanta, Georgia, United States

Atlanta, Georgia, United States

Chamblee, Georgia, United States

Macon, Georgia, United States

Savannah, Georgia, United States

Ammon, Idaho, United States

Idaho Falls, Idaho, United States

Idaho Falls, Idaho, United States

Idaho Falls, Idaho, United States

Allen Park, Michigan, United States

Dearborn Heights, Michigan, United States

Southfield, Michigan, United States

Minneapolis, Minnesota, United States

Great Falls, Montana, United States

Hastings, Nebraska, United States

Lincoln, Nebraska, United States

Norfolk, Nebraska, United States

Omaha, Nebraska, United States

Omaha, Nebraska, United States

Bronx, New York, United States

Cincinnati, Ohio, United States

South Euclid, Ohio, United States

Gresham, Oregon, United States

Charleston, South Carolina, United States

North Charleston, South Carolina, United States

Simpsonville, South Carolina, United States

Nashville, Tennessee, United States

Beaumont, Texas, United States

Del Rio, Texas, United States

Fort Worth, Texas, United States

Houston, Texas, United States

Houston, Texas, United States

League City, Texas, United States

Richmond, Texas, United States

San Antonio, Texas, United States

Layton, Utah, United States

Roy, Utah, United States

Syracuse, Utah, United States

Buenos Aires, Ciudad De Buenos Aires, Argentina

Buenos Aires, , Argentina

Salvador, Bahia, Brazil

Belo Horizonte, Minas Gerais, Brazil

Porto Alegre, Rio Grande Do Sul, Brazil

Porto Alegre, Rio Grande Do Sul, Brazil

Ribeirão Preto, São Paulo, Brazil

São Paulo, , Brazil

Sapporo, Hokkaido, Japan

Kagoshima Shi, Kagoshima, Japan

Kawagoe, Saitama, Japan

Edogawa Ku, Tokyo, Japan

Fukui Shi, , Japan

Fukui, , Japan

Fukuoka, , Japan

Osaka, , Japan

Butere, , Kenya

Kericho, , Kenya

Nairobi, , Kenya

Bayamon, , Puerto Rico

Guayama, , Puerto Rico

San Juan, , Puerto Rico

San Juan, , Puerto Rico

Brits, , South Africa

Johannesburg, , South Africa

Johannesburg, , South Africa

Bangkok, , Thailand

Bangkok, , Thailand

Bangkok, , Thailand

Chiang Mai, , Thailand

Hat Yai, , Thailand

Khon Kaen, , Thailand

Tarzana, California, United States

Victorville, California, United States

Orlando, Florida, United States

Allen Park, Michigan, United States

Simpsonville, South Carolina, United States

Houston, Texas, United States

San Antonio, Texas, United States

Layton, Utah, United States

Salvador, Bahia, Brazil

Porto Alegre, Rio Grande Do Sul, Brazil

Sã£O Paulo, São Paulo, Brazil

Puerto Montt, , Chile

Kagoshima, , Japan

Lizuka Shi, , Japan

Mexico City, , Mexico

East London, , South Africa

Pretoria, , South Africa

Southampton, Hampshire, United Kingdom

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported